Milestone Group Inc. boosted its position in UnitedHealth Group Inc (NYSE:UNH) by 32.5% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 1,321 shares of the healthcare conglomerate’s stock after buying an additional 324 shares during the quarter. Milestone Group Inc.’s holdings in UnitedHealth Group were worth $322,000 as of its most recent filing with the SEC.

Other institutional investors have also recently made changes to their positions in the company. Canton Hathaway LLC acquired a new stake in UnitedHealth Group in the 1st quarter valued at approximately $36,000. Truvestments Capital LLC acquired a new position in shares of UnitedHealth Group during the 1st quarter worth approximately $42,000. Coastal Capital Group Inc. acquired a new position in shares of UnitedHealth Group during the 2nd quarter worth approximately $45,000. Creative Financial Designs Inc. ADV increased its position in shares of UnitedHealth Group by 89.6% during the 1st quarter. Creative Financial Designs Inc. ADV now owns 201 shares of the healthcare conglomerate’s stock worth $50,000 after purchasing an additional 95 shares during the last quarter. Finally, Capital Advisors Ltd. LLC increased its position in shares of UnitedHealth Group by 235.7% during the 2nd quarter. Capital Advisors Ltd. LLC now owns 235 shares of the healthcare conglomerate’s stock worth $57,000 after purchasing an additional 165 shares during the last quarter. 85.65% of the stock is currently owned by institutional investors and hedge funds.

Several research analysts have recently commented on UNH shares. ValuEngine downgraded UnitedHealth Group from a “hold” rating to a “sell” rating in a research note on Thursday, April 18th. SunTrust Banks reduced their target price on UnitedHealth Group to $300.00 and set a “buy” rating for the company in a research note on Wednesday, April 17th. They noted that the move was a valuation call. Morgan Stanley lifted their target price on UnitedHealth Group from $285.00 to $298.00 and gave the stock an “overweight” rating in a research note on Friday, July 12th. Bank of America reiterated a “buy” rating and set a $290.00 target price (down from $320.00) on shares of UnitedHealth Group in a research note on Wednesday, April 17th. Finally, Raymond James lifted their target price on UnitedHealth Group from $265.00 to $300.00 and gave the stock a “buy” rating in a research note on Friday, July 19th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and eighteen have given a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $295.06.

UNH traded up $2.53 during trading on Wednesday, hitting $245.73. The stock had a trading volume of 1,070,816 shares, compared to its average volume of 4,651,164. The stock has a 50 day simple moving average of $251.38. The company has a market capitalization of $235.62 billion, a price-to-earnings ratio of 19.08, a price-to-earnings-growth ratio of 1.33 and a beta of 0.61. UnitedHealth Group Inc has a one year low of $208.07 and a one year high of $287.94. The company has a current ratio of 0.67, a quick ratio of 0.67 and a debt-to-equity ratio of 0.62.

UnitedHealth Group (NYSE:UNH) last released its quarterly earnings results on Thursday, July 18th. The healthcare conglomerate reported $3.60 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $3.46 by $0.14. The business had revenue of $60.60 billion during the quarter, compared to the consensus estimate of $60.59 billion. UnitedHealth Group had a return on equity of 25.20% and a net margin of 5.51%. The firm’s quarterly revenue was up 8.0% on a year-over-year basis. During the same period in the previous year, the company posted $3.14 EPS. As a group, sell-side analysts expect that UnitedHealth Group Inc will post 14.82 EPS for the current fiscal year.

In other news, Director Richard T. Burke sold 10,000 shares of the company’s stock in a transaction on Wednesday, May 29th. The stock was sold at an average price of $241.99, for a total transaction of $2,419,900.00. Following the completion of the sale, the director now directly owns 187,663 shares in the company, valued at approximately $45,412,569.37. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director William C. Ballard, Jr. sold 12,000 shares of the company’s stock in a transaction on Tuesday, July 23rd. The shares were sold at an average price of $255.31, for a total value of $3,063,720.00. Following the sale, the director now owns 61,309 shares of the company’s stock, valued at $15,652,800.79. The disclosure for this sale can be found here. Insiders sold a total of 37,000 shares of company stock valued at $9,195,620 over the last 90 days. 0.82% of the stock is currently owned by corporate insiders.

UnitedHealth Group Profile

UnitedHealth Group Incorporated operates as a diversified health care company in the United States. It operates through four segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health and well-being services to individuals age 50 and older, addressing their needs for preventive and acute health care services, as well as services dealing with chronic disease and other specialized issues for older individuals; and Medicaid plans, Children's Health Insurance Program, and health care programs; and health and dental benefits.

Featured Story: Golden Cross

Want to see what other hedge funds are holding UNH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for UnitedHealth Group Inc (NYSE:UNH).

Institutional Ownership by Quarter for UnitedHealth Group (NYSE:UNH)

Receive News & Ratings for UnitedHealth Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UnitedHealth Group and related companies with MarketBeat.com's FREE daily email newsletter.